News & Videos - CURIS INC.

NEW YORK, NY / ACCESSWIRE / August 3, 2017 / Curis, Inc. (NASDAQ: CRIS ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 3, 2017 at 8:30 AM Eastern Time. To listen to the event live - visit https://www.investornetwork.com/company/23823 . Replay Information The replay will be available online at https://www.investornetwork.com/company/23823 . About Investor Network Investor Network (IN) is a new financial content community, serving millions of...

NEW YORK, NY / ACCESSWIRE / May 4, 2017 / Curis, Inc. (NASDAQ: CRIS ) will be discussing their earnings results in their Q1 Earnings Call to be held Thursday, May 04, 2017 at 8:30 AM Eastern Time. To listen to the event live – visit https://www.investornetwork.com/company/23823 . Replay Information The replay will be available online at https://www.investornetwork.com/company/23823 . About Investor Network Investor Network (IN) is a new financial content community, serving millions of unique...

LEXINGTON, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancer, today announced that it has exercised its option to extend the exclusivity period with Aurigene under the collaboration, license and option agreement established in January, 2015. As previously reported, the extension of exclusivity is associated with a payment of $7.5...

LEXINGTON, Mass., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that on January 1, 2017, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 185,000 shares of Curis common stock to eight new employees, with a grant date of...

LEXINGTON, Mass., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancer, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted full approval to Erivedge ® (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally...

LEXINGTON, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced the appointment of Lori A. Kunkel, M.D. to its Board of Directors. Dr. Kunkel currently serves on the Board of Directors at Loxo Oncology, where she was formerly Acting Chief Medical Officer. Prior to Loxo Oncology, Dr. Kunkel served as Chief Medical...

LEXINGTON, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancer, today presented preliminary clinical pharmacokinetic (PK) and early biomarker data from the ongoing dose escalation stage of CA-170’s Phase 1 trial at the Society for Immunotherapy of Cancer (SITC) 31 st Annual Meeting & Associated Programs in National Harbor, MD. CA-170...

LEXINGTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today reported its financial results for the third quarter ended September 30, 2016. "We are pleased with our progress this quarter, and remain focused on patient enrollment within our two clinical programs. CA-170’s Phase 1 trial is progressing rapidly through the...

LEXINGTON, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will release its third quarter 2016 financial results on Thursday, November 3, 2016, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT. To access the live conference...

LEXINGTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that on October 5, 2016, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 225,000 shares of Curis common stock to three new employees, with a grant date of...

CA-327, a PD-L1/TIM3 dual antagonist designed and optimized by Aurigene, licensed as the 2 nd oral small molecule immuno-oncology development candidate under the Curis Aurigene collaboration LEXINGTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancer, today announced the expansion of its pipeline with CA-327, an oral, small molecule...